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Open Forum Infectious Diseases
MAJOR ARTICLE

Erik R. Dubberke,1 Justin T. Puckett,2 Engels N. Obi,3 Sachin Kamal-Bahl,2 Kaushal Desai,3 Bruce Stuart,4 and Jalpa A. Doshi5,6
1

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, USA, 2COVIA Health Solutions, Lansdale, Pennsylvania, USA, 3Merck & Co, Inc, Rahway, New Jersey,
USA, 4School of Pharmacy, University of Maryland, Baltimore, Maryland, USA, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, and 6Leonard Davis
Institute of Health Economics, Philadelphia, Pennsylvania, USA

Background. The 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA)
Clostridium (Clostridioides) difficile infection (CDI) guideline update recommended treatment with fidaxomicin or vancomycin for
CDI. We aimed to examine outpatient CDI treatment utilization before and after the guideline update and compare clinical
outcomes associated with fidaxomicin versus vancomycin use.
Methods. A pre-post study design was employed using Medicare data. CDI treatment utilization and clinical outcomes (4- and
8-week sustained response, CDI recurrence) were compared between patients indexed from April–September 2017 (preguideline
period) and those indexed from April–September 2018 (postguideline period). Clinical outcomes associated with fidaxomicin
versus vancomycin were compared using propensity score–matched analyses.
Results. From the pre- to postguideline period, metronidazole use decreased (initial CDI: 81.2% to 53.5%; recurrent CDI: 49.7%
to 27.6%) while vancomycin (initial CDI: 17.9% to 44.9%; recurrent CDI: 48.1% to 66.4%) and fidaxomicin (initial CDI: 0.87% to
1.63%; recurrent CDI: 2.2% to 6.0%) use increased significantly (P < .001 for all). However, clinical outcomes did not improve. In
propensity score–matched analyses, fidaxomicin versus vancomycin users had 4-week sustained response rates that were higher by
13.5% (95% confidence interval [CI], 4.0%–22.9%; P = .0058) and 30.0% (95% CI, 16.8%–44.3%; P = .0002) in initial and recurrent
CDI cohorts, respectively. Recurrence rates were numerically lower for fidaxomicin in both cohorts.
Conclusions. Vancomycin use increased and metronidazole use decreased after the 2017 guideline update. Fidaxomicin use
increased but remained low. Improved outcomes associated with fidaxomicin relative to vancomycin suggest benefits from its
greater use in Medicare patients.
Keywords. Clostridioides difficile infection; fidaxomicin; Medicare; metronidazole; vancomycin.

Clostridioides difficile infection (CDI) is the most common
healthcare-associated infection in adults [1–3] and is associated
with significant morbidity, mortality, and healthcare utilization
and costs [4–7]. Historically, the standard of care for treating
CDI was limited to vancomycin or metronidazole [8].
Fidaxomicin (Dificid), was approved by the United States
(US) Food and Drug Administration in May 2011, offering a
new treatment option [9, 10]. As evidence on CDI treatments
accumulated, major changes in CDI treatment guidelines
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were introduced. In the 2017 update to the Infectious
Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA) clinical practice
guidelines, metronidazole was demoted from a first-line agent
for nonsevere CDI [3]. Vancomycin and fidaxomicin were rec
ommended as first-line agents for initial or recurrent CDI epi
sodes. The guidelines were recently updated in June 2021 with
fidaxomicin as the sole recommended first-line agent and van
comycin as an alternative agent [11].
Despite these guideline changes, limited data exist on their im
pact on treatment utilization and clinical outcomes. Clancy et al
[12] found that use of vancomycin and fidaxomicin increased
considerably whereas metronidazole use decreased in the 18
months following publication of the 2017 guidelines update com
pared to the 18 months before. Gentry et al [13] did not find an
improvement in clinical outcomes after the shift away from met
ronidazole as the preferred treatment option. However, clinical
outcomes were not examined in this study. Furthermore, no study
has exclusively examined the impact in elderly patients, who are
disproportionately affected by CDI [14].
Impact of Updated IDSA CDI Guidelines • OFID • 1

Downloaded from https://academic.oup.com/ofid/article/9/10/ofac435/6686548 by Washington University in St. Louis user on 23 November 2022

Impact of Updated Clinical Practice Guidelines on
Outpatient Treatment for Clostridioides difficile Infection
and Associated Clinical Outcomes

METHODS
Study Design and Data Source

A pre-post study design was employed for the first study aim. For
the second study aim, we conducted a propensity score (PS)–
matched analysis of the pooled pre- and postguideline cohorts
treated with fidaxomicin versus vancomycin. The study used
2016–2018 claims data from the Medicare program, the largest
source of health insurance for the elderly in the US (additional
background on the Medicare data is available in the
Supplementary Materials). The data included claims for patients
with fee-for-service Medicare Part A and B–covered medical
claims as well as Medicare Part D prescription drug claims.
Study Samples

Figure 1 shows the schematic used to identify the base sample
of initial CDI episode patients from which the recurrent CDI
episode sample was generated. Subjects were selected based
on the first outpatient claim with a CDI diagnosis
(International Classification of Diseases, Tenth Revision,
Clinical Modification [ICD-10-CM] code A047.xx) between 1
April 2017 and 30 September 2017 (preguideline cohort) and
between 1 April 2018 and 30 September 2018 (postguideline
cohort). The first diagnosis identified was classified as the initial
CDI diagnosis. The postguideline period duration was limited
and only incorporated the year 2018 since those were the latest
data available at the time of the study. Identical April–
September time periods in the pre- and postguideline cohorts
correspond to those used by Furuya-Kanamori et al [15] and
were intended to capture seasonality in CDI infection rates.
Given the limitations inherent with administrative claims
data, several sample inclusion/exclusion criteria were necessary
to ensure all patients included had complete data available to
conduct the planned analyses, had a new episode of CDI, and
had clear evidence of receiving a CDI treatment so as to allow
the assessment of clinical outcomes using claims-based defini
tions. Hence, sample selection for the pre- and postguideline
cohorts was restricted to patients with outpatient claims be
cause inpatient Medicare claims do not list medications needed
to ascertain CDI treatment regimens. Dates for the first
2 • OFID • Dubberke et al

observed outpatient CDI claims were designated as index dates
from which clinical outcomes were tracked. Patients were in
cluded if they were at least 66 years of age and had continuous
Medicare fee-for-service coverage for 12 months before and
3 months after their index dates (or until death). Additional se
lection criteria included absence of CDI in the 12 weeks prior to
index date (to ensure initial CDI episode) and evidence of CDI
prescription fill (vancomycin, fidaxomicin, or metronidazole)
during follow-up. Patients were excluded if they were hospital
ized between the index date and first CDI prescription fill date,
had evidence of first CDI prescription fill occurring >7 days af
ter index CDI diagnosis date, received multiple prescriptions
for the same or different CDI treatments on the first CDI pre
scription fill date, or received >15 or <10 days’ supply on their
first CDI prescription fill (Supplementary Tables 1 and 2).
Preguideline observations were excluded for patients selected
in both the pre- and postguideline cohorts to avoid repeated
observations (Supplementary Table 1).
From the pre- and postguideline cohorts of patients with an
initial CDI episode as outlined above, we selected a subset of
patients with 4-week CDI recurrence (definition shown in
“Outcome Variables”) and applied additional selection criteria
(see Supplementary Tables 3 and 4 for additional selection cri
teria) to derive the recurrent CDI pre- and postguideline co
horts. For the second study aim (the PS-matched analysis),
we limited our analysis to vancomycin and fidaxomicin users
and pooled them across the pre- and postguideline cohorts to
maximize sample sizes.
Outcome Variables

Outcomes were assessed over a 3-month follow-up period for
both the pre- and postguideline cohorts. These included first
CDI prescription filled (ie, metronidazole, vancomycin, or fi
daxomicin) on or after the index date and 4-week and 8-week
sustained response and CDI recurrence rates. Sustained re
sponse was defined as having evidence of clinical resolution
(no additional CDI treatment or hospitalization with a diagno
sis of CDI before or within 1 day after the supply of the first CDI
prescription is exhausted) and no evidence of CDI recurrence.
CDI recurrence was defined as any evidence of a new CDI treat
ment or hospitalization with a diagnosis of CDI within 4 weeks
(or 8 weeks) of the date of completion of the index CDI pre
scription among patients with clinical resolution.
Other Variables

Covariates captured included demographic characteristics (age,
sex, race/ethnicity, census region, and metropolitan status),
Medicare Part D plan coverage, low-income subsidy status,
plan type, CDI-related costs in the 12 months before the index
date, and clinical factors believed to influence CDI drug selec
tion and recurrence rates. The clinical variables included CDI
history, evidence of compromised immunity, Elixhauser
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Using real-world claims data for elderly Medicare beneficia
ries with CDI treated in the outpatient setting, we aimed to (1)
evaluate changes in CDI treatment utilization and clinical out
comes before versus after the 2017 IDSA guidelines update
among patients with initial and recurrent CDI and (2) compare
clinical outcomes in elderly Medicare beneficiaries receiving fi
daxomicin versus vancomycin as first-line treatment for initial
and recurrent CDI. Study findings should help inform CDI dis
ease management strategies in the outpatient setting and serve
as a useful benchmark while we wait for data to accumulate to
evaluate the more recent 2021 IDSA CDI guideline update.

comorbidities, renal impairment, hepatic impairment, Crohn
disease/ulcerative colitis, solid tumors, and medication use (an
tibiotics, gastric acid suppressors, laxatives, and nonsteroidal
anti-inflammatory drugs).
Statistical Analysis

The first study aim entailed descriptive and multivariable logis
tic regression analyses comparing rates of first-line CDI treat
ment utilization, sustained response, and CDI recurrence in
the pre- and postguideline cohorts, in the initial and recurrent
CDI samples. The key independent variable of interest in the
logistic regression models was patient membership in the
post- (vs pre-) guideline cohort. The models also included
the above-listed sociodemographic and clinical covariates
that may be associated with CDI drug selection, sustained re
sponse, and recurrence rates (see Supplementary Tables 5–8
for a detailed list of covariates).
For the second aim, PS-matched analyses were used to com
pare clinical outcomes between fidaxomicin and vancomycin
users. Separate PS models were estimated for the initial and re
current CDI samples. Multivariable logistic regression was used
to estimate the propensity for being a fidaxomicin user (vs van
comycin user) as a function of various combinations of
demographic and clinical variables designed to achieve
the best balance between the groups in the combined initial
CDI episode sample and recurrent episode sample (see
Supplementary Tables 9 and 10 for detailed list of covariates).
After generating the propensity scores, fidaxomicin users
were matched 1:1 with vancomycin users using a nearestneighbor matching approach with caliper widths set at 0.20
of the standard deviation of the logit of the propensity scores.
Plots of the distribution of the propensity scores in the fidaxo
micin and vancomycin groups were assessed to evaluate

common support before and after matching (Supplementary
Figures 1–4). Balance between the matched samples was assessed
based on whether the Cohen standardized difference (D) was
<10. We were unable to achieve acceptable balance on some co
variates (ie, Cohen D >10); we adjusted for this remaining imbal
ance by estimating the clinical outcomes using logistic
regressions among the PS-matched samples that included only
the unbalanced variables (ie, Part D benefit type in the initial
CDI episode PS-matched sample; sex, region, and Part D benefit
type for recurrent CDI episode PS-matched sample) as covari
ates in the regression models.
RESULTS
Changes in Treatment Utilization and Clinical Outcomes Before and After
Guideline Update

Initial CDI Sample

There were 7389 and 7746 patients with an initial CDI episode in
the pre- and postguideline periods, respectively (Supplementary
Tables 1 and 2). Both cohorts were similar in characteristics
(Table 1). Both cohorts were primarily White and primarily fe
male. Approximately 40% of both cohorts were aged 66–74 years
and >50% of both cohorts had ≥5 Elixhauser comorbidities.
Approximately two-thirds of both cohorts had exposure to mod
erate to high-CDI-risk antibiotics. Significant proportions had
renal impairment and cancer. The top panel in Figure 2 shows
CDI treatment utilization by choice of first-line agent in the
pre- and postguideline cohorts. Preguideline, 81.2% of CDI pa
tients were treated with metronidazole, which dropped to
53.5% in the postguideline period (relative change [RC],
–34.1%; P < .001). Most of the 27.7 percentage point decline in
metronidazole shifted to vancomycin (17.9% [preguideline peri
od] to 44.9% [postguideline period]; RC, +150.2%; P < .001).
Fidaxomicin use (0.87% in the preguideline period) increased
Impact of Updated IDSA CDI Guidelines • OFID • 3
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Figure 1. Sample selection schematic. Abbreviations: CDI, Clostridioides difficile infection; IDSA/SHEA, Infectious Diseases Society of America/Society for Healthcare
Epidemiology of America.

Table 1. Sample Characteristics by First-Line Clostridioides difficile Infection (CDI) Treatment Pre– and Post–Guideline Update, Among Medicare
Beneficiaries With an Initial or Recurrent CDI Episode
Initial CDI Episode

Recurrent CDI Episode

Pre
(n = 7389)

Post
(n = 7746)

Pre
(n = 779)

Post
(n = 837)

66–74

41.2%

41.4%

42.7%

40.0%

75–84

37.7%

39.4%

38.5%

42.7%

≥85

21.1%

19.2%

18.7%

17.3%

Male

32.3%

32.0%

32.5%

34.5%

Female

67.7%

68.0%

67.5%

65.5%

White

92.1%

93.1%

93.6%

95.2%

Black

3.8%

3.4%

3.3%

2.6%

Hispanic

1.0%

0.9%

a

a

3.2%

2.6%

a

a

Northeast

19.5%

20.3%

21.7%

19.4%

Midwest

27.9%

27.5%

30.2%

28.7%

South

34.6%

34.2%

31.2%

34.2%

West

18.1%

18.0%

16.9%

17.8%

Urban

76.8%

77.0%

77.7%

76.5%

Rural

23.2%

23.0%

22.3%

23.5%

Full or partial LIS

21.5%

19.9%

19.5%

15.8%

Non-LIS

78.5%

80.1%

81.5%

84.2%

Basic alternative

24.4%

24.7%

26.1%

24.5%

Enhanced alternative

44.5%

45.4%

43.8%

44.7%

Defined standard benefit

15.4%

15.3%

13.5%

14.6%

Other

15.7%

14.6%

16.7%

16.2%

Characteristic
Age

Race

Other
Census region

Metropolitan status

Part D LIS status

Part D drug benefit type

No. of Elixhauser comorbidities in the 12 mo preindex
0

2.5%

2.6%

4.7%

2.5%

1–2

15.7%

14.7%

18.1%

17.7%

3–4

21.2%

21.4%

24.6%

22.3%

≥5

60.7%

61.3%

52.5%

57.5%

Recurrent CDI risk factors
CDI within past 6 mo

4.1%

4.2%

3.9%

4.2%

27.2%

29.4%

24.8%

28.2%

1

70.2%

68.0%

72.5%

68.9%

2

28.2%

30.3%

>26.0%a

29.7%

3

1.6%

1.6%

Renal impairment

28.1%

28.4%

26.1%

27.5%

Hepatic impairment

12.4%

13.9%

87.3%

87.8%

5.0%

5.5%

4.7%

4.5%

21.9%

22.7%

20.3%

24.3%

Compromised immunity in the 12 mo preindexb
No. of recurrent CDI risk factorsc

a

1.3%

Key comorbidities in the 12 mo preindex

Crohn disease or ulcerative colitis
Cancer
Solid tumor

19.9%

20.3%

18.5%

20.9%

Hematologic malignancy

3.4%

3.8%

3.2%

4.7%

HSCT or SOT

2.5%

2.8%

2.6%

2.6%

68.2%

67.8%

73.3%

70.4%

63.9%

63.3%

69.7%

67.0%

Low-risk antibiotics

4.3%

4.5%

3.6%

3.3%

Gastric acid suppression

48.8%

48.9%

46.2%

47.9%

Recent history of medication use in the 3 mo preindex
Antibiotics
Moderate- to high-risk antibiotics

4 • OFID • Dubberke et al
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Sex

Table 1. Continued
Initial CDI Episode

Characteristic
Laxatives
NSAIDs

Pre
(n = 7389)

Recurrent CDI Episode

Post
(n = 7746)

Pre
(n = 779)

Post
(n = 837)

6.2%

6.5%

5.8%

7.3%

23.0%

24.1%

21.4%

23.7%

49.1%

48.7%

46.0%

46.0%

3.7%

4.0%

3.2%

3.2%

$43 908 ($58 233)

$43 047 ($54 526)

$37 839 ($50 002)

$40 340 ($54 712)

$1231 ($8645)

$1172 ($6770)

$875 ($5516)

$1223 ($8595)

Hospitalization

Healthcare costs, mean (SD)
All-cause costs in the 12 mo preindex
CDI-related costs in the 12 mo preindex

Abbreviations: CDI, Clostridioides difficile infection; HSCT, hematopoietic stem cell transplant; LIS, low-income subsidy; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation;
SOT, solid organ transplant.
a

Per Centers for Medicare and Medicaid Services policy, results based on cell sizes <11 and/or exact values for cell sizes ≥11 that may permit calculation of a cell size <11 cannot be displayed.

b

Patients were classified as having compromised immunity if they were a transplant recipient or had evidence of human immunodeficiency virus/AIDS, immunosuppressive agent use,
chemotherapy use, or hematological malignancy.
c

Age ≥65 years, CDI within past 6 months, immunocompromised.

by 0.8 percentage points (RC, +87.8%; P < .001), but its overall
utilization rate remained low in the postguideline period (1.63%).
Descriptive statistics for the clinical outcomes associated with
CDI treatment in the pre- and postguideline periods are presented
in Table 2. Over the pre/post periods, 4-week sustained response
rates dropped 2.1 percentage points (from 56.9% to 54.8%;
P = .01) and 8-week sustained response dropped 3.1 percentage
points (from 52.9% to 49.8%; P = .0002). Together with declines
in sustained response, CDI recurrence rates rose over the pre/
post period by 2.8 percentage points at 4 weeks and 3.9 points
at 8 weeks, both statistically significant at P < .05. Multivariable
logistic regressions confirmed these descriptive findings
(Supplementary Tables 5 and 6). For instance, even after adjust
ment the odds of fidaxomicin or vancomycin use relative to met
ronidazole use were nearly 4-fold higher (odds ratio [OR], 3.91
[95% confidence interval {CI}, 3.62–4.21]) in the postguideline
versus preguideline period. Similarly, even after adjustment, the
odds of having a 4-week sustained response were significantly low
er (OR, 0.93 [95% CI, .87–.99]) and the odds of having a 4-week
CDI recurrence were significantly higher (OR, 1.13 [95% CI,
1.05–1.22]) in the post- versus preguideline period.
Recurrent CDI Sample

There were 779 and 837 people in our recurrent CDI sample in the
pre- and postguideline periods, respectively (Supplementary
Tables 3 and 4). As with the initial CDI episode samples, there
was little change in characteristics between the pre- and postguide
line cohorts (Table 1). Relative to the initial CDI sample, the preand postguideline cohorts in the recurrent episode sample were
somewhat younger and exhibited slightly lower prevalence of
Elixhauser comorbidities and CDI risk factors but were far more
likely to suffer from hepatic impairment. In fact, >87% of all recur
rent patients had evidence of hepatic impairment. The bottom
panel of Figure 2 reports drug utilization rates for these patients.

As in the initial CDI sample, the largest fraction of recurrent pa
tients used metronidazole (49.7%) in the preguideline period, vir
tually the same as for vancomycin users (48.1%). Postguideline,
metronidazole use dropped by from 49.7% to 27.6% (RC,
–44.4%; P < .001), whereas vancomycin use increased from
48.1% to 66.4% (RC, +38.0%; P < .001). Fidaxomicin use increased
by 3.8 percentage points (from 2.2% to 6.0%; RC, +173.7%; P <
.001) and its overall use remained low in the postguideline period.
Sustained response rates were lower in the postguideline peri
od (52.2% [4 weeks] and 46.7% [8 weeks]) compared to the pre
guideline period (57.4% [4 weeks] and 53.3% [8 weeks]) in the
recurrent CDI sample (Table 2). For the CDI recurrence out
come, the increases were 2.3 percentage points at 4 weeks
(from 32.6% to 34.9%) and 4.3 points (from 37.4% to 41.7%)
at 8 weeks, but neither result was statistically significant.
Multivariable logistic regression analyses confirmed these de
scriptive findings (Supplementary Tables 7 and 8). For instance,
even after adjustment, the odds of fidaxomicin or vancomycin
use relative to metronidazole use were significantly higher
(OR, 1.75 [95% CI, 1.37–2.23]) in in the postguideline versus
preguideline period. Similarly, even after adjustment, the odds
of having a 4-week sustained response were significantly lower
(OR, 0.77 [95% CI, .62–.96]) and the odds of having a 4-week
CDI recurrence were not significantly different (OR, 1.24 [95%
CI, .96–1.60]) in the postguideline versus preguideline period.
Comparison of Clinical Outcomes for Fidaxomicin Versus Vancomycin

Initial CDI Episode Sample

There were 190 fidaxomicin users and 4800 vancomycin users
before PS matching in our initial CDI episode sample. A 1:1
match was found for all 190 fidaxomicin users. Patient charac
teristics for the matched sample in the PS analysis (190 subjects
in both the fidaxomicin and vancomycin groups) are presented
in Supplementary Table 9. Key findings from these logistic
Impact of Updated IDSA CDI Guidelines • OFID • 5
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All-cause hospitalization in the 12 mo preindex
CDI-related hospitalization in the 12 mo preindex

regression models are shown in Table 3. For patients in their
initial CDI episode, fidaxomicin was associated with a 4-week
sustained response that was 13.5 percentage points higher com
pared to vancomycin (71.7% vs 58.2%; P = .0058) and a 8-week
6 • OFID • Dubberke et al

sustained response rate 13.2 percentage points higher (63.2% vs
50.0%; P = .0114) compared to vancomycin (Table 3). Rates of
CDI recurrence for patients in their initial CDI episode were
numerically lower for fidaxomicin in both the 4-week (20.6%
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Figure 2. First-line use of Clostridioides difficile infection (CDI) treatments, pre– vs post–guideline update, among Medicare beneficiaries with an initial or recurrent CDI
episode. P < .001 for all results, based on χ2 test. Abbreviations: CDI, Clostridioides difficile infection; FDX, fidaxomicin; MTZ, metronidazole; VAN, vancomycin.

Table 2. Unadjusted Clinical Outcomes, Pre– Versus Post–Guideline
Update, Among Medicare Beneficiaries With Initial or Recurrent CDI
Episode
Pre
Outcome

Post

No.

(%)

7389

…

No.

(%)

P Value

Initial CDI episode
7746

…

Sustained response (4 wk)

4205

(56.9)

4247

(54.8)

.01

Sustained response (8 wk)

3907

(52.9)

3861

(49.8)

.0002

Among patients with a clinical
resolution

6097

…

6415

…

CDI recurrence (4 wk)

1892

(31.0)

2168

(33.8)

.001

CDI recurrence (8 wk)

2190

(35.9)

2554

(39.8)

<.0001

Recurrent CDI episode
All patient with recurrent CDI
episode

779

…

Sustained response (4 wk)

447

(57.4)

437

(52.2)

.0369

Sustained response (8 wk)

415

(53.3)

391

(46.7)

.0084

Among patients with a clinical
resolution

663

…

837

671

…

…

CDI recurrence (4 wk)

216

(32.6)

234

(34.9)

.3756

CDI recurrence (8 wk)

248

(37.4)

280

(41.7)

.1064

CDI recurrence was calculated only among patients with evidence of clinical resolution. P
values are based on χ2 test.
Abbreviation: CDI, Clostridioides difficile infection.

[fidaxomicin] vs 29.0% [vancomycin]) and 8-week (31.3% [fi
daxomicin] vs 38.9% [vancomycin]) comparisons, but the re
sults were not statistically significant.
Recurrent CDI Episode Sample

There were 67 fidaxomicin users and 931 vancomycin users be
fore PS matching in our initial CDI episode sample. A 1:1 match
was found for all 67 fidaxomicin users. Patient characteristics for
the best-matched sample in the PS analysis (67 subjects in both
the fidaxomicin and vancomycin arms) are presented in
Supplementary Table 10. In the recurrent CDI episode sample,
about 66% of patients in the fidaxomicin group and 60% of pa
tients in the vancomycin group received prior vancomycin ther
apy for their initial CDI episode. For patients receiving
fidaxomicin in their recurrent CDI episode, the 4-week sustained
response rate was 30.0 percentage points higher (75.1% vs 45.1%;
P = .0002) and the 8-week sustained response rate was 27.6 per
centage points higher (66.5% vs 38.9%; P = .0012) compared to
those receiving vancomycin (Table 3). Rates of CDI recurrence
were numerically lower for fidaxomicin in both the 4-week and
8-week comparisons, but the results were not statistically signifi
cant (which also did not permit reporting of the absolute rates per
Centers for Medicare and Medicaid Services [CMS] policy).
DISCUSSION

This study provides a comprehensive evaluation of the impact
of the 2017 IDSA/SHEA guideline update on drug utilization
and clinical outcomes, and the real-world comparative
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effectiveness of the first-line agents (fidaxomicin and vancomy
cin) recommended in this update, in the elderly Medicare pop
ulation. Our findings show that this guideline update led
clinicians to shift their choice of first-line agent from metroni
dazole to vancomycin and substantially less so to fidaxomicin.
The shift was dramatic with relative rate declines in metronida
zole use of 34% for initial CDI episodes and 42% for recurrent
CDI episodes. We also found no corresponding improvement
in sustained response and CDI recurrence in either initial or re
current CDI episodes after the guideline publication. Finally,
we found better clinical outcomes in patients receiving fidaxo
micin compared to vancomycin in both the initial and recur
rent CDI setting.
Our findings on the changes in CDI treatment utilization af
ter the 2017 guideline update in the Medicare population have
been reported in other patient populations. Clancy et al [12]
used US antibiotic prescription claims data across multiple in
surance segments and found that vancomycin and fidaxomicin
use increased, whereas use of metronidazole decreased in the 18
months following publication of the 2017 guideline update
compared to 18 months before. While the Clancy et al study
did not examine clinical outcomes, our study found that the de
crease in metronidazole use and an increase in the utilization of
vancomycin, one of the first-line treatments recommended in
the 2017 guideline update, was not accompanied by an im
provement in clinical outcomes. There are 3 potential reasons
for these mixed findings. First, in post-hoc analysis
(Supplementary Figure 5), we found that the sustained re
sponse rates and recurrence rates associated with vancomycin
were very similar to those associated with metronidazole in
our real-world study sample of elderly Medicare patients.
Second, fidaxomicin, found to have significantly better clinical
outcomes, had utilization rates that were too low to impact
changing population-level clinical outcomes between the preand postguideline periods. In other words, had there been a
greater shift to fidaxomicin prescribing after the 2017 guideline
update, we might have observed improved outcomes for the
study sample as a whole in the postguideline period. Third,
the CDI cases included in these analyses were nonsevere by vir
tue of needing to limit the population to patients treated in the
outpatient setting based on prescription data availability. The
greatest benefit of vancomycin over metronidazole is for initial
cure of more severe CDI episodes [16].
Our findings suggesting that fidaxomicin was superior to
vancomycin in achieving sustained response is supported in
prior literature [9, 10, 17–20]. Strikingly, the absolute differenc
es in the clinical outcomes observed in our real-world study
were quite similar to those reported in the fidaxomicin ran
domized trials [9, 10]. For example, the difference in 4-week
sustained response rates between fidaxomicin (71.7%) and van
comycin (58.2%) in the initial CDI episode sample was 13.5% in
our real-world study and 10.5% in the fidaxomicin randomized

Table 3. Clinical Outcomes Among Propensity Score–Matched Medicare Beneficiaries With Clostridioides difficile Infection (CDI) Initiating Fidaxomicin
Versus Vancomycin for an Initial or Recurrent CDI Episode With Regression Controlling for Unbalanced Variables

Outcome

Fidaxomicin

Vancomycin

Difference, %
(95% CI)

P Value (Clustered)a

Initial CDI episode
n = 190

71.7%

58.2%

13.5 (4.0–22.9)

.0058

Sustained response (8 wk)

63.2%

50.0%

13.2 (3.1–23.4)

.0114

n = 141

n = 141

CDI recurrence (4 wk)

20.6%

29.0%

−8.4 (−18.4 to 1.6)

.101

CDI recurrence (8 wk)

31.3%

38.9%

−7.6 (−18.9 to 3.7)

.1893

Among patients with a clinical resolution

Recurrent CDI episode
n = 67

n = 67

Sustained response (4 wk)

75.1%

45.1%

30.0 (16.8–44.3)

.0002

Sustained response (8 wk)

66.5%

38.9%

27.6 (12.0–43.2)

.0012

n = 40

n = 40

CDI recurrence (4 wk)

b

b

−10.3 (−28.9 to 6.9)

.292

CDI recurrence (8 wk)

b

b

−13.3 (−35.1 to 8.8)

.255

All patients with recurrent CDI episode

Among patients with a clinical resolution

Abbreviations: CDI, Clostridioides difficile infection; CI, confidence interval.
a

P values are based on logistic regressions with robust standard errors for clustering by matched pair.

b

Per Centers for Medicare and Medicaid Services policy, results based on cell sizes <11 and/or exact values for cell sizes ≥11 that may permit calculation of a cell size <11 cannot be displayed.

trials [9]. Furthermore, a meta-analysis of data from these ran
domized trials conducted by Crook et al [17] found that fidax
omicin was also superior in reducing CDI symptoms and CDI
recurrence. We also observed an absolute difference in the
4-week CDI recurrence rates (−8.4% in initial CDI episodes
[20.6% for fidaxomicin and 29.0% for vancomycin] and –
10.3% [data not reported due to CMS policy restricting cell siz
es <11] in the recurrent CDI episodes) that was in favor of fi
daxomicin but did not reach statistical significance, possibly
due to small sample sizes. Again, the absolute reduction in
CDI recurrence was similar to the randomized trials. While it
should be noted that some observational studies conducted in
certain high-risk groups [18, 19] have not found a meaningful
difference in outcomes between fidaxomicin and vancomycin,
several other observational studies conducted by Goldenberg
et al [20], Gallagher et al [21], and Polivkova et al [22] have
demonstrated fidaxomicin’s superiority over vancomycin in
treating CDI. The evidence on the superiority of fidaxomicin
over vancomycin has also been acknowledged in the latest up
date to IDSA guidelines for CDI treatment published in 2021
[11], which now recommends fidaxomicin as first-line treat
ment for both initial and recurrent CDI episodes, with vanco
mycin an acceptable alternative. Future research is necessary to
see whether this most recent update has further shifted treat
ment patterns toward fidaxomicin and its associated impact
on clinical outcomes.
Our study has several limitations. As with all administrative
claims data, coding errors are possible. Medicare claims do not
report laboratory values or microbiological data necessary to de
termine CDI severity and certain CDI risk factors; we therefore
lacked positive CDI test results to confirm a patient’s diagnosis
8 • OFID • Dubberke et al

or patient symptoms to document active infection. In addition,
the codes used to identify outcomes and other variables in our
claims-based study are not validated; thus, the study is prone
to measurement error. To the extent there are systematic differ
ences in any of these factors across the fidaxomicin versus van
comycin groups, it may have resulted in unmeasured
confounding of our study findings. We were also unable to assess
any CDI diagnoses that may have occurred outside of our study
period. Furthermore, it is important to note that our study only
examined CDI diagnosed in the outpatient setting, a necessary
limitation in order to link drug treatment to initial diagnosis,
limiting our results to nonsevere CDI. Thus, findings may not
be generalizable to other care settings and severe CDI. Our study
sample excluded patients who had multiple prescriptions for
CDI treatment on their index date or had a prescription with a
supply of <10 days or >15 days. These patients were not receiv
ing treatment consistent with guidelines and were excluded to
permit a more robust evaluation of the impact of treatment
guidelines on outcomes. Finally, given that the guidelines were
published and available to all clinicians in the country, it was im
possible to establish a contemporaneous control group. Thus,
some of the treatment utilization changes we observed may be
due to other factors; however, the magnitude of the changes in
vancomycin and metronidazole use were large and occurred
over such a short period of time that any explanation other
than the guidelines update appears implausible.
We conclude that the 2017 IDSA guideline update for CDI
treatment led to considerable increases in vancomycin use
and decreases in metronidazole use in the months immediately
following publication in 2018. Fidaxomicin use increased but
remained low. Our findings regarding better outcomes
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associated with fidaxomicin in treating both initial and recur
rent CDI suggest benefits from its greater use in the Medicare
population and support the 2021 change in IDSA guidance rec
ommending fidaxomicin over vancomycin.
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